From the immunotherapeutic perspective, the main caveats associated with the use of systemic recombinant IL-2 therapy relate to low therapeutic levels in the tumor microenvironment (TME) and the activation of immunosuppressive cells, such as TRegs (3, 7). The gene discussed is IL2; the disease is neoplasm.